‘Not against transparency, but against Act 723': MMA confirms private doctors' march on Tuesday
MMA private practitioners section chairman Datuk Dr Parmjit Singh Kuldip Singh said the walk, which addresses the government's new medicine price transparency policy, will proceed lawfully unless objections arise.
'We wish to reiterate that doctors are not against price transparency but are strongly opposed to Act 723 being used on the medical profession,' he said in a statement today.
He said that the gathering will be attended by other doctors' associations and will culminate in the handing over of a memorandum to the Prime Minister's Office.
MMA had previously said that it was against the use of a non-medical act — the Price Control and Anti-Profiteering Act 2011 (Act 723) — on medical practitioners.
It said that it preferred medicine price transparency laws to be put under the Private Healthcare Facilities and Services Act 1998 (Act 586).
The protest is also set to address the 33-year stagnation of private general practitioner (GP) consultation fees.
The mandatory display of medicine prices at private healthcare facilities, enforced under Act 723, came into effect on May 1, following a joint announcement by the Health Ministry and the Domestic Trade and Cost of Living Ministry.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
17 hours ago
- Barnama
MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation
-- Photograph for illustrative purposes MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation KUALA LUMPUR, Aug 15 (Bernama) -- MBSB Investment Bank (MBSB IB) has maintained its 'positive' recommendation on the insurance sector, citing attractive valuations and high dividend yields despite persistent healthcare inflation and delays in healthcare cost-control reforms. In a research note today, the bank said healthcare inflation remains a 'tricky issue to fix' as higher spending on the sector appears inevitable. 'Our primary concern is that if healthcare inflation is still rampant, what will happen at the end of Bank Negara Malaysia's three-year cap on medical insurance premium hikes? 'But there are multiple tailwinds -- a cheap price point, attractive dividend yields, a potential windfall in investment income, and encouraging progress by insurers in addressing the healthcare inflation problem -- making the sector due for a positive re-rating,' it said. The bank noted that companies under its coverage are market leaders, enabling them to withstand challenges better than most. MBSB IB said medical cost pressures are being fuelled by private hospitals rejecting proposed cost freezes, opposing pharmaceutical price controls, and what insurers describe as 'buffet table syndrome', where high claims are linked to increased service use without clear medical need. It also pointed to Malaysia's relatively low preventive healthcare spending and intensifying competition in healthcare tourism from Thailand, Indonesia and Singapore. However, the bank highlighted some progress in tackling medical inflation, including the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025, which will require mandatory medicine price displays in the private sector by 2026. 'The initiative aims to enable the public to make informed choices by knowing the prices in advance and to encourage competitive medical pricing, although it has faced resistance, with several medical groups filing a judicial review," it said. The bank added that another factor is the decline in active pharmaceutical ingredient (API) raw material prices to pre-pandemic levels, after surging during the pandemic and staying elevated for several years due to logistical constraints, factory closures and increased demand for healthcare products. MBSB IB's top picks are Allianz Malaysia Bhd, with a target price of RM21.59, and Syarikat Takaful Malaysia Keluarga Bhd, with a target price of RM4.59, while LPI Capital Bhd is also rated 'buy'. -- BERNAMA
BusinessToday
18 hours ago
- BusinessToday
Insurance Sector Poised For Healthy Gain Despite Inflation Worries
MBSB Investment Bank Bhd (MBSB Research) has maintained a POSITIVE call on the insurance sector, citing attractive valuations, solid dividend yields, and signs of progress in tackling healthcare inflation despite persistent headwinds. Allianz and Syarikat Takaful Malaysia Bhd (STMB) remain top picks with 'buy' recommendations and target prices of RM21.59 and RM4.59, respectively. The optimism comes even as the government once again postponed the mandatory rollout of the diagnosis-related groups (DRG) payment system for private hospitals, pushing the implementation from mid-2025 to 2027. The DRG framework, widely used in countries such as Thailand and Indonesia, aims to standardise hospital reimbursement based on diagnosis and treatment rather than charging per service. An interim version will begin in selected private hospitals this year, alongside a basic Medical and Health Takaful Insurance platform scheduled for 2026. Insurers have been taking firmer steps to address medical cost inflation, though MBSB noted that increased healthcare spending remains unavoidable. Malaysia's healthcare tourism industry is under competitive pressure from regional players such as Thailand and Singapore, with private hospitals investing heavily in high-end facilities to attract overseas patients. The Association of Private Hospitals Malaysia (APHM) has pushed back against several insurer proposals, including freezing private hospital costs for three years and regulating pharmaceutical prices, arguing these could compromise care standards and limit access to new treatments. Rising claims have also been attributed by APHM to more severe patient cases, potentially linked to post-pandemic complications. Preventive care remains a weak spot, with just 6–7% of the Health Ministry's budget allocated to prevention, far below the treatment allocation. Still, MBSB highlighted recent progress. The Price Control and Anti-Profiteering Order 2025 will require private sector medicine price displays by 2026, promoting transparency and competition. The cost of active pharmaceutical ingredients has also retreated to pre-pandemic levels, easing some pressure on drug prices. Furthermore, co-pay uptake is gaining traction, with Allianz reporting encouraging adoption rates and insurers seeing lower health loss ratios in early 2025. MBSB Research emphasised that while healthcare inflation is unlikely to disappear, continued insurer initiatives, combined with a low sector price point and the potential for higher investment income, provide a case for a positive re-rating. The firm noted that companies under its coverage are market leaders, better positioned to navigate economic uncertainty and the structural challenges of rising reinsurance costs. However, risks remain, including the possibility of slower premium growth if the economy weakens and the threat of persistent healthcare inflation even after the DRG rollout.
Borneo Post
2 days ago
- Borneo Post
KPJ Sabah launches Zero Harm Campaign to promote safer healthcare
Mohamad Faizal Mohamed, Chief Executive Officer of KPJ Sabah Specialist Hospital (centre), in a group photo with the resident consultants, staff of KPJ Sabah, and guest speakers from KPJ headquarters. KOTA KINABALU (Aug 14): KPJ Sabah Specialist Hospital has reaffirmed its commitment to a harm-free healthcare environment by organising its Zero Harm Campaign at the hospital recently. The campaign aims to foster a workplace culture where no injuries or accidents occur, while creating a safe, reliable and harm-free healthcare setting for patients, staff and visitors. Its key objectives include eliminating preventable harm such as falls, medication errors, surgical errors and infections; promoting a culture of safety through open communication, accountability and continuous learning; strengthening compliance with safety standards and best practices; improving patient outcomes via proactive risk identification and prevention strategies; and empowering staff at all levels through training and awareness. In Malaysia, hospital-level Zero Harm initiatives generally fall under the Private Healthcare Facilities and Services Act 1998 (Act 586), administered by the Ministry of Health (MOH). Guest speakers from KPJ Healthcare Berhad's headquarters included Dr Rafiza Mohamed Nazri, Head of Clinical Governance; Jayanthi Marimuthu, Group Chief Nursing Officer; and Zarihasyum Wan Zein, Head of Pharmacy and Allied Health. Dr Rafiza spoke on ensuring compliance with policies, guidelines and work instructions to prevent sentinel events; Jayanthi discussed infection prevention and control as well as the Safe Surgery, Save Lives programme; while Zarihasyum highlighted initiatives to enhance medication safety and reduce errors across all KPJ hospitals. Also present were Dr Lim Keok Tang, Medical Director, and Mohamad Faizal Mohamed, Chief Executive Officer of KPJ Sabah Specialist Hospital. During the event, management and staff pledged their commitment to the Zero Harm Campaign, promising to prioritise safety in their work and personal lives. The pledge emphasises personal responsibility, hazard identification and reporting, safe practices, continuous improvement, communication and accountability. Moving forward, KPJ Sabah Specialist Hospital will continue to enhance employee and patient safety by implementing specific initiatives and goals, and by expanding the Zero Harm culture across the organisation. For more information, visit:
